Search clinical trials for: pegylated interferon (pegIFN)

Total 2732 results

Suzhou Ribo Life Science Co. Ltd.

Recruiting

A Study of RBD1016 in CHB Participants

Chronic Hepatitis b

Sweden
Bristol-Myers Squibb

Completed

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen (LIRA-B)

Hepatitis B Virus

Australia, France, Germany, Korea, Republic of, Taiwan, United States, Canada, Italy, Netherlands, Singapore, Hong Kong
University of Modena and Reggio Emilia
Merck Sharp & Dohme LLC

Unknown

Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC) (MEN_BOC)

Menopause | Chronic Hepatitis C

Italy
Poitiers University Hospital

Completed

Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase

Chronic Phase of Chronic Myeloid Leukemia
GlaxoSmithKline

Completed

Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB) (B-Together)

Hepatitis B

Russian Federation, Spain, Canada, China, United States, Italy, Japan, Korea, Republic of, Poland, South Africa, United Kingdom
Boehringer Ingelheim

Completed

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Hepatitis C

United States, Austria, Belgium, Canada, France, Germany, Japan, Korea, Republic of, Portugal, Romania, Russian Federation, Spain, Switzerland, Taiwan, United Kingdom
Boehringer Ingelheim

Completed

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

Hepatitis C

Japan
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

Hepatitis C

United States, Canada, Korea, Republic of, Puerto Rico, Taiwan
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)

Hepatitis C

Austria, Belgium, France, Germany, Japan, Portugal, Romania, Russian Federation, Spain, Switzerland, United Kingdom
Huashan Hospital

Completed

Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy

Chronic Hepatitis B

China
Merck Sharp & Dohme LLC

Terminated

A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)

Malignant Melanoma
HepNet Study House, German Liverfoundation
Gilead Sciences; Hannover Medical School; Hoffmann-La Roche

Completed

HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis (HIDIT-II)

Hepatitis D

Germany, Greece, Romania
National Institute of Allergy and Infectious Diseases...
FDI Clinical Research

Terminated

Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection (LATHCV)

Hepatitis C | HIV

United States
University Hospital, Bonn
Hoffmann-La Roche

Terminated

Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients

HIV Infections | Chronic Hepatitis B

Germany
Norwegian University of Science and Technology

Completed

Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia (NordCML007)

Leukemia, Myeloid, Chronic-Phase

Sweden, Finland, Norway
Boehringer Ingelheim

Withdrawn

A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection

Hepatitis C, Chronic
Qin Ning

Unknown

Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients (NPGV)

Chronic Hepatitis b
Boehringer Ingelheim

Completed

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

Hepatitis C, Chronic

United States, Brazil, France, Germany, Italy, Spain, Switzerland, United Kingdom
Henan Provincial People's Hospital
Xiamen Amoytop Biotech Co., Ltd.

Completed

Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy

Chronic Hepatitis B

China
Xiamen Amoytop Biotech Co., Ltd.
Peking University People's Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C (PEGIFN)

Chronic Hepatitis C

China
Foundation for Liver Research

Completed

Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB (PEGON)

Chronic Hepatitis B

Netherlands, China
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Chronic Hepatitis C | Hepatitis C Virus (HCV) Infection

United States, Puerto Rico
The Second Affiliated Hospital of Chongqing Medical...
The First Affiliated Hospital of Nanchang University; First Affiliated Hospital... and other collaborators

Unknown

Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides

Hepatitis B
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)

Renal Insufficiency
AbbVie

Completed

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
Sociedad Andaluza de Enfermedades Infecciosas

Completed

Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4

Liver Cirrhosis | HIV Infection | Hepatitis C Virus

Spain
Third Affiliated Hospital, Sun Yat-Sen University
Peking University; First People's Hospital of Foshan; Shenzhen Third People's...

Unknown

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

Chronic Hepatitis B

China
Third Affiliated Hospital, Sun Yat-Sen University
Peking University; Huazhong University of Science and Technology; First People... and other collaborators

Unknown

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

Chronic Hepatitis B

China
Boehringer Ingelheim

Completed

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

Hepatitis C, Chronic

United States, Argentina, Australia, Austria, Canada, Czech Republic, France, Germany, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Switzerland, United Kingdom
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)

Melanoma | Renal Cell Carcinoma
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Hepatitis C | Pharmacokinetics

Japan
AbbVie

Completed

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

Hepatitis C Virus (HCV)
National Institute of Diabetes and Digestive and...

Withdrawn

Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B

Chronic Hepatitis B

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)

Hepatitis C
AbbVie

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (DORA)

Hepatitis C Virus (HCV)

United States, Belgium, Canada, Germany, Japan, Puerto Rico, Russian Federation, Spain, United Kingdom
Merck Sharp & Dohme LLC

Terminated

Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)

Hepatitis C, Chronic
Pusan National University Yangsan Hospital
Pusan National University Hospital; Inje University; Severance Hospital; Soon Chun... and other collaborators

Unknown

PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)

Chronic Hepatitis C

Korea, Republic of
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Hepatitis C, Chronic

Japan
Tongji Hospital

Unknown

A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B (COST)

Chronic Hepatitis B

China
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (PENGUIN)

Hepatitis B, Chronic

Taiwan, Poland, Japan, New Zealand
Janssen Research & Development, LLC

Terminated

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection (PENGUIN-2)

Hepatitis B, Chronic

Taiwan, Spain, Canada, Poland, United States, Japan
Huashan Hospital

Unknown

Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy

Chronic Hepatitis B

China
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment (EXPEDITION-5)

Hepatitis C Virus (HCV)

United States, Canada, Germany, Greece, Italy, Korea, Republic of, Poland, Puerto Rico, Spain, Sweden
M.D. Anderson Cancer Center
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Infection

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B, Chronic

France, Taiwan, Canada, United States, Germany, Spain, Japan, Russian Federation, Turkey, United Kingdom
Amsterdam UMC, location VUmc
Merck Sharp & Dohme LLC; Novartis; Uppsala University Hospital

Terminated

Nilotinib Plus Pegylated Interferon-α2b in CML

Chronic Myeloid Leukemia

Netherlands, Denmark, Sweden, Finland, Norway
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Hepatitis C, Chronic

Japan
AbbVie

Completed

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (ENDURANCE-5 6)

Hepatitis C Virus (HCV)

United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

Japan
Merck Sharp & Dohme LLC

Withdrawn

A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)

Hepatitis C

3

Subscribe